GRIP Molecular Technologies, MTL partner on at-home disease testing platform
The collaboration has resulted in a clinical feasibility trial of GRIP Molecular Technologies’ patented electronic biosensor technology which…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
19 Dec 23
The collaboration has resulted in a clinical feasibility trial of GRIP Molecular Technologies’ patented electronic biosensor technology which…
13 Dec 23
The objectives of the study include assessing the Freenome's test's sensitivity, specificity, positive and negative predictive values in…
12 Dec 23
The new screening method is designed to use antigens to evaluate multiple disease markers, assess several samples simultaneously,…
21 Nov 23
The trial is intended to assess and compare the group of Medicare beneficiaries who undergo standard care along…
21 Nov 23
UDX’ Signal-C is designed to detect methylation DNA patterns and fragments released by circulating colorectal cancer tumours in…
15 Nov 23
The next-generation screening test of Geneoscopy is a multi-target stool RNA biomarker panel, designed to identify colorectal cancer…
15 Nov 23
Both companies will work together to integrate and improve a diagnostic system to be used in clinical environments…
10 Nov 23
The EsoGuard Esophageal DNA test is intended to help in preventing cancer and associated death through early detection…
06 Nov 23
Under the partnership, affiliates of Solaris Health will use Velsera’s Clinical Genomics Workspace platform to provide inherited cancer…
01 Nov 23
GMED, a French Notified Body specialising in medical device assessments, issued the certification contract authorising the use of…